The goal of the therapy in type 2 diabetes is defined according to hemoglobin A1c (HbA1c) level, which reflects chronic hyper glycemia. In 2009, an acceptable metabolic control was defined as HbA1c <7%. But recently, the American Diabetes Association (ADA) and the
European Association for the Study of Diabetes (EASD) released a consensus position on personalized HbA1c goals, centered in the patient. Available therapies to treat and control type 2 diabetes are reviewed; traditional therapies as metformin, sulfonylureas, and insulin and new therapies as GLP-1 analogues and DPP-4 inhibitors.
Araya Q., V. . (2012). Diagnóstico actual y alternativas de tratamiento médico en diabetes mellitus tipo 2. Revista Hospital Clínico Universidad De Chile, 23(3), pp. 197–203. https://doi.org/10.5354/2735-7996.2012.73719
